证券日报网讯2月3日，爱美客（300896）在互动平台回答投资者提问时表示，截至目前，公司暂无港股 上市计划。 ...

Core Viewpoint - The ChiNext Medical Index (970082) closed at 3876.07 points on February 3, with a gain of 2.37% and a trading volume of 13.236 billion yuan, indicating positive market sentiment in the medical sector [1]. Group 1: Index Performance - The ChiNext Medical Index saw 49 constituent stocks rise, with NuoSiGe leading the gains at 8.76% [1]. - The index's turnover rate was 1.71%, reflecting moderate trading activity [1]. Group 2: Top Constituents - The top ten constituents of the ChiNext Medical Index include: - YuanEr Eye Hospital (sz300015) with a weight of 9.18% and a latest price of 11.04 yuan, up 1.28% [1]. - MaiRui Medical (sz300760) with a weight of 8.95% and a latest price of 188.15 yuan, up 0.56% [1]. - TaiGe Medical (sz300347) with a weight of 8.52% and a latest price of 63.20 yuan, up 4.97% [1]. - KangLong HuaCheng (sz300759) with a weight of 7.18% and a latest price of 29.61 yuan, up 2.10% [1]. - LePu Medical (sz300003) with a weight of 4.96% and a latest price of 17.83 yuan, up 1.89% [1]. - New Industry (sz300832) with a weight of 4.73% and a latest price of 54.50 yuan, up 2.60% [1]. - AiMeiKe (sz300896) with a weight of 4.49% and a latest price of 147.57 yuan, up 4.56% [1]. - YingKe Medical (sz300677) with a weight of 4.14% and a latest price of 40.55 yuan, up 1.38% [1]. - FuRui Medical (sz300049) with a weight of 3.55% and a latest price of 67.33 yuan, up 1.45% [1]. - HuaDa Gene (sz300676) with a weight of 3.15% and a latest price of 50.30 yuan, up 2.57% [1]. Group 3: Capital Flow - The net inflow of main funds into the ChiNext Medical Index constituents totaled 145 million yuan, while retail investors experienced a net outflow of 106 million yuan [1]. - The detailed capital flow indicates that TaiGe Medical had a main fund net inflow of 10.514 million yuan, while retail investors had a net outflow of 18.28% [2].

Summary of Key Points Core Viewpoint - The A-share market experienced significant block trading activity on February 3, with a total transaction value of 2.236 billion yuan, highlighting notable trading in specific stocks such as Shanghai Airport, Zijin Mining, and Longjing Environmental Protection [1]. Group 1: Block Trading Activity - A total of 80 stocks underwent block trading, with Shanghai Airport leading at 349 million yuan, followed by Zijin Mining at 274 million yuan and Longjing Environmental Protection at 161 million yuan [1]. - Among the stocks traded, 7 were sold at par value, 2 at a premium, and 71 at a discount, indicating a predominance of discounted trades [1]. Group 2: Premium and Discount Rates - The stocks with the highest premium rates were DeMa Technology at 5.67% and Shen High-Speed at 2.01% [1]. - The stocks with the highest discount rates included Kai Fa Technology at 29.94%, New Wave Shares at 23.56%, and Ai Meike at 23.43% [1]. Group 3: Institutional Buying and Selling - The top institutional buying positions included Shanghai Airport at 349 million yuan, Longxin Zhongke at 116 million yuan, and Xinyuan Shares at 60.575 million yuan [2]. - The leading institutional selling positions were Nanxin Technology at 8.4 million yuan and Guobo Electronics at 4.1784 million yuan [2].

Core Viewpoint - Recently, Aimeike (300896) announced that its subsidiary REGEN received a decision from the Shenzhen International Arbitration Court, which ruled not to implement the temporary measures previously ordered by an emergency arbitrator on September 10, 2025 [1] Group 1 - On September 10, 2025, the emergency arbitrator of the Shenzhen International Arbitration Court had issued a decision that restricted REGEN Biotech, Inc. from selling AestheFill products in China before the arbitration ruling was made [1] - The court's decision also stated that REGEN must acknowledge that Datuo Medical Devices (Shanghai) Co., Ltd. is the exclusive distributor of AestheFill products in China and must continue to supply the products to Datuo as per the agreement [1]

Group 1 - The medical beauty sector increased by 3.9% on February 3, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 147.57, up 4.56%, and Huaxi Biological at 48.81, up 3.45% [1] Group 2 - The medical beauty sector saw a net inflow of 72.0481 million yuan from main funds, while retail funds experienced a net outflow of 41.6043 million yuan [1] - Ai Meike had a net inflow of 85.9952 million yuan from main funds, but retail funds saw a net outflow of 38.6841 million yuan [2] - Huaxi Biological experienced a net outflow of 10.4367 million yuan from main funds, with a net inflow of 14.2989 million yuan from speculative funds [2]

Group 1 - The major indices collectively rose on February 3, with the National Bio-Medical Index (399441) increasing by 1.15%. Notable stocks included Zhaoyan New Drug and Aimeike, both rising over 4%, while Tigermed and Huaxi Biological increased by over 3%, and Kailaiying rose nearly 3% [1] - The Bio-Medical ETF (159859) had a trading volume exceeding 65 million yuan, ranking first among its peers. The net inflow for this ETF on the previous trading day (February 2) was 67.29 million yuan, and it has seen continuous net inflows over the past 10 days, accumulating over 440 million yuan [1] - The latest circulating share of the Bio-Medical ETF is 9.569 billion shares, with a total market size of 3.674 billion yuan, making it the largest in its category [1] Group 2 - The Shanghai Municipal Government's work report emphasized the need to deepen the construction of an international economic center, focusing on modern industrial systems and supporting sectors such as bio-medicine, integrated circuits, and artificial intelligence [2] - According to Zhongtai Securities, the pharmaceutical market opportunities are expected to revolve around thematic opportunities, with potential performances in brain-computer interfaces, AI healthcare, and small nucleic acids. There is also a strategic emphasis on the raw material drug sector, which is at a bottom range and may see a mid-term positive cycle due to rising chemical prices and new business additions [2]

Core Viewpoint - The domestic AI-assisted medical technology is advancing, with significant developments in the approval of innovative medical devices and the application of AI in healthcare, indicating a potential for rapid growth in the AI+ healthcare market [1][2]. Group 1: Market Performance - As of February 3, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.57%, with notable gains from stocks such as Aimeike (+4.07%), Jianfan Bio (+2.36%), and Xinhengcheng (+2.29%) [1]. - The Medical Innovation ETF (516820) also rose by 0.57%, with the latest price reported at 0.36 yuan [1]. Group 2: AI in Healthcare - AI applications in smart healthcare are becoming mature, particularly in medical imaging diagnostics, where AI assists doctors in improving interpretation efficiency [2]. - Recent AI medical products have accelerated their market entry, including the "Cervical Cell Digital Pathology Image Auxiliary Diagnosis Software" approved in January 2026 and the "Yuan Zhi" model from United Imaging, which achieved over 95% accuracy in complex lesion diagnosis [2]. - The combination of technological iteration and policy support is expected to drive rapid growth in the domestic AI+ healthcare market [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and R&D innovation capabilities, reflecting the overall performance of profitable and growth-oriented medical and medical device companies [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, collectively accounting for 63.9% of the index [2].

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]

Core Viewpoint - The silver economy in China is experiencing significant growth, with projections indicating that the market size will exceed 16 trillion yuan by 2030, driven by the evolving consumption habits of the new generation of elderly consumers [1][2]. Group 1: Market Overview - In 2019, the market size of China's silver economy reached 4.3 trillion yuan, growing to 7.1 trillion yuan in 2023, and is expected to further increase to 8.3 trillion yuan in 2024. By 2030, the overall market size is anticipated to surpass 16.2 trillion yuan, indicating substantial potential for the silver economy [2]. - The new generation of elderly consumers exhibits significant differences in wealth levels, family structures, and consumption habits compared to previous generations, prompting companies to adapt their business strategies to meet these new consumer demands [2]. Group 2: Retail Sector - Leading retail companies such as Bailian Group and Chongqing Department Store are developing business models tailored to the purchasing habits and preferences of elderly consumers, addressing both social and purchasing needs [2]. - Supermarket chains like Hema and Yonghui are enhancing their product offerings and introducing "silver community canteens" to increase foot traffic and conversion rates among elderly shoppers [2]. Group 3: Gold and Jewelry Sector - Middle-aged and elderly consumers have historically been the primary market for gold products, driven by a focus on value preservation and brand loyalty. Companies like Caibai and Lao Fengxiang are leveraging their strong brand foundations to cater to this demographic [3]. - These companies are enhancing their product offerings through collaborations and improving customer loyalty via robust after-sales services, positioning themselves to benefit from the expanding customer base [3]. Group 4: Beauty and Personal Care Sector - The proportion of elderly consumers in the beauty and medical aesthetics markets is steadily increasing, with significant growth potential in both volume and pricing, similar to trends observed in mature overseas markets [4]. - Leading companies with strong upstream raw material capabilities and comprehensive solutions, such as Huaxi Biological and Aimeike, are expected to benefit from the rising sales among elderly consumers [4]. - Companies focused on elderly care, like Kelaibao, are also poised to gain from the expanding target audience in the personal care sector [4].

Investment Rating - The report maintains a "Recommended" investment rating for the beauty and personal care industry [5][26]. Core Insights - Betaini Group's brand Winona has officially entered the Middle East market, expanding its overseas footprint by opening its first offline store in Doha Mall, Qatar, marking it as the first Chinese functional skincare brand registered in Qatar [5][24]. - The report highlights the global development strategy of companies in the medical beauty sector, emphasizing a transition from single product output to a systematic compliance layout and the value output of "Chinese solutions" [5][26]. - The report suggests focusing on companies with core raw material technology advantages and a full industry chain matrix, such as Marubi Biotechnology, Huaxi Biological, and Juzhi Biological [5][26]. Summary by Sections Recent Market Performance - From January 26 to January 30, 2026, the Shenwan Beauty and Personal Care Index decreased by 3.92% [13]. - The top five gainers in the sector included companies like Four Seasons Medicine and Yisi Health, while the biggest losers included Lafang Cosmetics and Shanghai Jahwa [13]. Industry News - Time安生物's siRNA weight loss drug targeting ALK7 has achieved global simultaneous submission for clinical trials, showcasing the company's global development strategy [18][19]. - The customs authority has introduced nine measures to support the development of the beauty industry, focusing on building Guangzhou as a global cosmetics manufacturing and consumption center [20]. Key Company Announcements - Baiya Co., Ltd. announced plans for share reduction by major shareholders, while Jeya Co., Ltd. plans to recognize asset impairment losses to reflect its financial status accurately [21][22]. Weekly Insights - The opening of Winona's store in Qatar is a significant step in the brand's globalization strategy, receiving recognition from local medical and retail sectors [24][25]. - The report emphasizes the importance of systematic compliance capabilities and clinical validation in the development of medical beauty enterprises [26]. Investment Recommendations - The report recommends focusing on companies with strong R&D capabilities and market positioning, such as Betaini and Aimeike, while also considering traditional brands that are actively transforming [26].